lectroconvulsive therapy (ECT) was introduced to psychiatric practice in 1938. 1 While ECT was widely hailed as an effective treatment of schizophrenia, it was quickly recognized as especially effective for affective disorders. The use of ECT in schizophrenia decreased with the introduction of the psychotropic drugs but has remained a significant treatment option particularly for medication-resistant patients. 2 Practice surveys document that schizophrenia is the second most common diagnostic indication for the use of ECT in the United States, 3 and use of ECT in schizophrenia is also high in Canada and many European and developing countries. 4Y13 Nevertheless, there is a lack of consensus about the role of ECT in schizophrenia. 14 Indeed, the modern literature on the clinical features predictive of ECT outcome in schizophrenia consists of a single study of a mixed sample of 17 patients with schizophrenia and schizoaffective disorder. 15 Fundamental issues, such as the predictive value of negative symptoms, have not been addressed. In addition, there is virtually no information on the nature of the symptoms that improve when treatment-resistant schizophrenia (TRS) patients receive ECT.
Recently, we reported 293 patients with TRS who were treated with the combination of ECT and a typical antipsychotic, flupenthixol. 16 All of these patient samples were collected from a series of our previous ECT studies. 17Y22 One hundred sixty patients (54.6%) met a response criterion. The responders were younger and had shorter durations of illness and current episode, more admissions, and little family history of schizophrenia. Duration of current episode, pre-ECT Global Assessment of Functioning (GAF) scale scores, duration of illness, pre-ECT MiniYMental State Examination (MMSE) scores, duration of the previously failed neuroleptic trials, family history of schizophrenia, and paranoid type could predict the therapeutic outcome. The treatment resulted in marked improvement in positive symptoms but had a minimal effect or led to a worsening of negative symptoms. 16 Unfortunately, subsequent analysis of the data of this report 16 identifies 40 patients who participated in these studies 17Y22 twice. After excluding these 40 patients, the data of a cohort of 253 TRS patients underwent a more accurate and methodologically sound statistical reanalysis to identify predictors of response and the nature of symptomatic improvement to ECT. This study did not test the relative efficacy of this combination treatment relative to pharmacological alternatives or ECT alone. Rather, among the patients receiving this combination treatment, we examined (1) the demographic and clinical history features associated with response, (2) the symptom profile predictive of response, and (3) the profile of symptomatic improvement. Given the sex differences in the age of onset of schizophrenia, 23, 24 premorbid functioning, 25, 26 neurobiological and neuropsychological correlates, 27Y29 responsiveness to pharmacological treatment, 30, 31 and long-term course and functional outcome, 25, 32 sex effects were closely examined. We examined these issues in a cohort receiving a combination treatment because there is substantial evidence that in TRS patients, combination treatment is more effective than treatment with either ECT or pharmacology alone. 33 
MATERIALS AND METHODS

Subjects
Modifying the criteria used in the original clozapine trial, 34 253 TRS patients were recruited from one university hospital and 2 state mental hospitals in Bangkok and Nonthaburi in Thailand between November 1, 1995, and December 31, 2002.
To be included in the study, in the current episode, patients must not have benefited sufficiently from 2 or more courses of neuroleptic medications from at least 2 different classes. The duration of each neuroleptic treatment period was at least 6 weeks and did not result in clinically significant symptomatic relief. To qualify as adequate, the dosage of each neuroleptic trial had to be at least 750 mg/d of chlorpromazine equivalents (CPZE). The duration of illness had to be more than 2 years. Diagnosis was based on the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, criteria.
35 Consensus was required among the patient's clinical team on the diagnosis and subtype of schizophrenia and the concurrence for the diagnosis with the patient's past medical records. A baseline Brief Psychiatric Rating Scale (BPRS) score of 37 or higher (18 items, rate on a 0Y6 scale 36 ) was also required for study inclusion, and all the patients presented with psychotic exacerbation. Age was restricted to between 16 and 50 years, inclusive. Patients with current alcohol or substance abuse, known sensitivity to the medications used in ECT, or serious medical conditions, as assessed by history, physical examination, and pertinent laboratory tests (complete blood cell count, electrolytes, and ECG), were excluded. Written consent was obtained from the patients and/or their guardians after complete description of the study. Of the 253 patients, 159 (67.7%) were treated exclusively on an inpatient basis, 54 (21.3%) were treated on a partial outpatient basis, and 40 (15.8%) were treated only as outpatients. This study was approved by the ethics committee of the Faculty of Medicine of Srinakharinwirot University and the National Review Board of Research Studies in Humans of Thailand.
Treatment
Psychotropic medications were withdrawn at least 5 days before the start of ECT, and flupenthixol was started immediately without a washout. Flupenthixol was started at 12 mg/d for the first week and then maintained at 24 mg/d (1200 mg of CPZE), contingent on tolerability, until completion of the ECT course. All the patients received trihexyphenidyl (4Y15 mg/d) to prevent extrapyramidal symptoms, and in 45 patients, diazepam at 5 to 20 mg/d (maximal, 3 doses during study) was used for excessive agitation. No other psychotropics were administered.
Electroconvulsive therapy was administered 3 times per week using a constant current and a brief pulse stimulus with either a Mecta SR1 (Mecta Corporation, Tualatin, Ore; n = 157) or Thymatron DGx device (Somatics, Inc, Lake Bluff, Ill; n = 96). The anesthetic medications were thiopenthal (2Y4 mg/kg) and succinylcholine (0.5Y1 mg/kg), used in the lowest doses required to induce anesthesia and provide adequate muscular relaxation. All the patients were treated with the traditional bilateral electrode placement. At the first treatment session, seizure threshold was determined using the empirical titration procedure. 37 An adequate seizure was defined as at least 30 seconds of tonic-clonic motor activity with EEG evidence of a seizure. One adequate seizure was obtained at each treatment. Electrical dosage was maintained at the threshold level unless seizure manifestations were inadequate. In such cases, charge was increased by 50%.
Response Classification
Patients who received 20 ECT treatments at the schedule of 3 per week and had final BPRS scores higher than 25 were classified as nonresponders. Patients who achieved a BPRS score of 25 or lower during the regular treatment course entered a 3-week stabilization period. During this period, ECT was given 3 times per week during the first week and then once weekly during the second and third weeks. If the BPRS score was 25 or higher during this period and the total number of treatments was less than 20, the patient returned to the regular schedule of 3 treatments per week. Responders were restricted to patients who completed the 3-week stabilization period, during which the BPRS score assessed before each treatment was consistently below 25. Although arbitrary, the choice of a score of 25 as the cutoff for designating response was also conservative, as clinically significant improvement may be observed with higher levels of symptoms. Given the inclusion requirement of a baseline BPRS score of 37, the minimum reduction among responders in BPRS score could be 32.4%.
Outcome Measures
Brief Psychiatric Rating Scale Ratings
The BPRS ratings were obtained just before the start of ECT, before each treatment, and 1 week after the end of the treatment course. Only the baseline and final BPRS ratings were examined here. The original 18-item BPRS was used, although it was modified by scale anchors for each item to enhance reliability. 38 Each item was scored on a 0-to-6 scale. However, in the analyses of percentage change in BPRS item and factor scores, ratings were converted to the more common 1-to-7 range to avoid division by zero. These ratings were provided by 5 nurses who had undergone extensive training in the use of this instrument before study participation. Interrater reliability was assessed at regular intervals (approximately 3 months), and intraclass correlation coefficients across the raters at the multiple assessments ranged from 0.93 to 0.97. Scores for the 5 traditional BPRS factors were computed as the mean item score per factor. This approach was chosen, as opposed to summing items within a factor, because a differing number of items contributes to each factor. The factors and constituent items were thought disturbance (conceptual disorganization, grandiosity, hallucinatory behavior, and unusual thought content), anxiety-depression (somatic concern, anxiety, guilt feelings, and depressive mood), withdrawal-retardation (emotional withdrawal, motor retardation, blunted affect, and disorientation), activation (tension, mannerisms and posturing, and excitement), and hostility-suspiciousness (hostility, suspiciousness, and uncooperativeness).
Other Ratings
The GAF was assessed at study entry and end, and the MMSE 39 was assessed at the same time as the BPRS.
Statistical Analyses
All analyses of variance (ANOVAs), multivariate ANOVAs (MANOVAs), and log-linear analyses used response status (responder vs nonresponder) and sex as between-subject factors. Post hoc comparisons of significant ANOVA effects were based on Fisher least significant difference. The significance of MANOVA effects was assessed with the F test associated with Wilks lambda. All tests were 2-tailed, and an alpha level of 0.05 was used. 45.32 Using ANOVA, the response status and sex groups were compared in the treatment parameters. Seizure threshold and motor and EEG seizure duration measures were logarithmically transformed to achieve normal distributions.
The ANOVAs and the log-linear analyses were used to examine the relations of demographic and clinical features to response status. The variables with significant univariate association with clinical outcome were submitted to a simultaneous logistic regression analysis with response status as the categorical dependent measure. This analysis was conducted across the total sample and separately for each sex.
To examine the baseline symptom profile associated with clinical outcome, a repeated measures MANOVA was conducted with the 5 BPRS factor scores as dependent measures. A similar analysis was conducted with scores on 18 BPRS items as the dependent measures. Given the sex differences in the symptoms associated with response, a separate simple logistic regression was conducted for each sex, determining the crude odds ratio of each item that separated responders and nonresponders. To evaluate the sensitivity and specificity of response prediction based on clinical features and symptom profiles, predictive (classificatory) discriminant analyses were also conducted using the prior probabilities observed in the sample.
To determine the profile of symptom change after the treatment, MANOVAs were conducted both on the percentage change in BPRS factor scores and the percentage change in the 18 BPRS items. The effect sizes for change were computed for the BPRS factors and each BPRS item. The descriptive discriminant functions and structure coefficients that optimally distinguished the change in BPRS in item scores of responders and nonresponders were computed for each sex.
RESULTS
One hundred thirty-eight (54.5%) of the 253 patients met the criteria for response. The mean (SD) BPRS score at the final assessment was 27.4 (11.9), and the mean (SD) reduction in the BPRS was 41.5% (25.0). The mean (SD) change in the MMSE over the study period was an improvement of 9.1% (20.3), with a mean (SD) post-ECT absolute score of 24.4 (5.3). However, there was no relationship between the extent of change in BPRS and MMSE scores (r 251 = 0.08, P = 0.22). Table 1 shows the demographic and clinical characteristics of all the 253 TRS patients as a function of sex and a response status. Information about the ECT parameters is presented in Table 2 .
Relations of Demographic and Clinical Characteristics to Therapeutic Outcome
As seen in Table 1 , the ANOVAs and the log-linear analyses on baseline demographic and clinical features indicated that the responders were significantly younger, had shorter duration of illness, shorter duration of current episode, and a history of more frequent psychiatric admissions. The responders were also less likely to have a positive family history of schizophrenia and considerably more likely to meet the criteria for the paranoid subtype relative to the nonresponders. The responders and the nonresponders did not differ in any of the measures of treatment history and were equivalent in total BPRS scores at study entry. However, the responders had higher scores in the baseline measures of global function (GAF) and cognitive status (MMSE).
These analyses also produced several interactions between response status and sex. Post hoc comparisons indicated that the interaction with age (F 1,249 = 3.88, P = 0.05) was due to female nonresponders being older than all the other groups (P e 0.004). Similarly, the interaction with duration of illness (F 1,249 = 15.12, P G 0.0001) was due to a markedly longer duration among 156 (22) 4.21
G0.0001
147 (31) 148 (21) 0 the female nonresponders compared with all the other groups (P G 0.0001). The interaction on GAF (F 1,249 = 4.15, P = 0.04) and MMSE scores (F 1,249 = 7.23, P = 0.008) were due to superior global functioning (P e 0.09) and global cognitive status (P e 0.001) in female responders relative to all the other groups. Finally, as shown in Table 1 , the interaction on diagnostic subtype (W 2 1 = 11.05, P = 0.001) was due to a marked excess of paranoid schizophrenia among the male responders (73.0%) compared with the male nonresponders (37.0%), but the rates were equivalent among the female responders (66.7%) and the female nonresponders (60.7%).
Treatment Variables
The ANOVA indicated that compared with the nonresponders, the responders received markedly fewer treatments ( Table 2 ). The ANOVAs also produced main effects of sex for the mean dose of thiopental (F 1,249 = 26.19, P G 0.0001) and succinylcholine (F 1,249 = 15.60, P G 0.0001). Because anesthetic dosing was based on weight, the female patients received lower absolute doses.
Predictor Variables for Therapeutic Outcome
Across the sample, the unique predictive value of patient age, duration of illness, episode duration, number of psychiatric admissions, diagnostic subtype (paranoid vs others), family history of schizophrenia, and GAF and MMSE scores were assessed with a logistic regression on response status. As seen in Table 3 , the duration of the index episode was by far the most potent predictor of clinical outcome in the total sample and in the separate analyses restricted to the male and female patients. Age was no longer a predictor, and total duration of illness had a significant relation only among females. Thus, longer duration of episode, but not necessarily longer duration of illness, had a negative predictive value with respect to clinical outcome. Of note, as in the univariate analyses, other predictive relationships differed by sex. Among males, more frequent psychiatric admissions and the paranoid subtype were associated with positive clinical outcome. Among females, shorter duration of illness, negative family history for schizophrenia, and higher baseline MMSE scores were associated with response.
Baseline Symptom Profiles and Therapeutic Outcome
The MANOVA on BPRS factor scores yielded a main effect of subscale (F 4,246 = 272.47, P G 0.0001) and an interaction between response status and subscale (F 4,246 = 8.38, P G 0.0001), without an interaction between response status, sex, and subscale (F 4,246 = 0.83, P = 0.51). As seen in Table 4 , compared with the nonresponders, the responders had significantly higher baseline scores for the anxiety-depression subscale and lower scores for the withdrawal subscale. This pattern was manifested by both the male and female patients. These findings suggested that greater severity of affective symptoms and lesser severity of negative symptoms (eg, disorientation and blunted affect) predicted positive clinical outcome independent of sex.
To test potential clinical utility, a predictive discriminant analysis was conducted, predicting response status on the basis of the 5 BPRS baseline factor scores. Accuracy of classification was only 66.0%, with 103 (74.6%) of 138 responders correctly identified and 64 (55.6%) of 115 nonresponders correctly identified.
Because the analysis of factor scores may obscure more consistent relations with specific BPRS items, a MANOVA was conducted on the 18 items. There was a main effect of item The t tests were conducted comparing responders and nonresponders on baseline BPRS item scores. Greater severity at baseline in a specific set of symptoms (emotional withdrawal, conceptual disorganization, mannerisms and posturing, and disorientation) was associated with nonresponse for both the male and female patients (data not shown). In contrast, high suspiciousness was associated with superior outcome among male patients, whereas greater affective symptoms (anxiety, guilt, and depressive mood) and hallucinatory behavior were associated with superior outcome among female patients.
Given these sex differences, for each sex, the baseline scores for the 18 BPRS items were submitted to simple logistic regression to derive the linear function best separating the responders from the nonresponders (Table 5 ). Confirming the univariate analyses, for both sexes, greater severity of emotional withdrawal, conceptual disorganization, mannerisms and posturing, and disorientation were associated with nonresponse. For male patients alone, greater blunted affect was associated with nonresponse and greater suspiciousness was associated with positive response. For female patients alone, higher scores for anxiety, guilt feelings, depressive mood, and hallucinatory behavior were associated with positive response.
Given that there was only partial overlap between the sexes in the symptom profiles associated with treatment response, a predictive (classificatory) discriminant analysis was performed separately for each sex using the 18 BPRS item scores. For male patients, the overall accuracy of classification was 76.1% (responders, 82.5%; nonresponders, 68.5%). For female patients, the overall accuracy was 81.6% (responders, 84.0%; nonresponders, 78.7%). The MANOVA on the percentage improvement in scores for the 5 BPRS factors yielded main effects of response status (F 1,249 = 154.76, P G 0.0001) and BPRS subscale (F 4,246 = 40.97, P G 0.0001) and interactions between response status and sex (F 1,249 = 3.75, P = 0.05) and response status and BPRS subscale (F 4,246 = 2.78, P = 0.03). There were no significant interactions involving sex and BPRS subscale. The interaction of response status and sex was due to the greater symptomatic improvement across subscales in female compared with male responders. The interaction between response status and BPRS subscale was mainly due to a substantially smaller difference in change on the withdrawal-retardation factor between the responders and the nonresponders than on other factors. Figure 1 presents the mean percentage improvement on each BPRS factor as a function of response status and sex. The BPRS factors differed markedly in degree of improvement, and this pattern was observed across all the 4 subgroups. Across the total sample, the effect sizes for improvement were thought disturbance, 1.48; activation, 1.21; hostility-suspiciousness, 1.08; anxiety-depression, 0.53; and withdrawal-retardation, j0.14. The withdrawal-retardation factor showed no change among the responders (t 137 = j0.28, P = 0.78), whereas there was a significant degree of deterioration in this factor score among the nonresponders (t 114 = j4.73, P G 0.0001). These findings indicated that across the response and sex groups, symptomatic improvement was greatest for the BPRS thought disturbance, activation, and hostility-suspiciousness factors and substantial but intermediate for the anxiety-depression factor, whereas the withdrawalretardation factor showed evidence of worsening. The MANOVA on the percentage change in each BPRS item produced main effects of response status (F 1,249 = 118.01, P G 0.0001) and BPRS item (F 17,233 = 24.23, P G 0.0001) and interactions between response status and sex (F 1,249 = 6.02, P = 0.01), response status and BPRS item (F 17,233 = 3.42, P G 0.0001), sex and BPRS item (F 17,233 = 1.83, P = 0.03), and response status, sex, and BPRS item (F 17,233 = 2.48, P = 0.001). Table 6 presents the mean percentage change and effect size for change across the sample for each BPRS item. Five symptoms showed especially marked improvement and thus especially large effect size: conceptual disorganization, tension, mannerisms and posturing, hostility, and unusual thought content. Three symptoms showed significant worsening: motor retardation, blunted affect, and disorientation. A descriptive discriminant analysis was conducted for each sex to derive the linear function best separating responders and nonresponders on the basis of percentage change in the BPRS items. The structure coefficients indicating the weighting of each item are also presented in Table 6 . There was remarkable similarity between the sexes in the changes in item scores associated with response. The correlation among males for the scores on the discriminant function derived among only males or females was 0.89 (df = 115, P G 0.0001). The correlation for females was 0.91 (df = 134, P G 0.0001). The correlation between the structure coefficients for each sex was 0.80 (df = 16, P G 0.0001). Based on the structure coefficients, for both sexes, improvement in conceptual disorganization, mannerisms and posturing, and unusual thought content best separated responders and nonresponders, whereas changes in emotional withdrawal, grandiosity, blunted affect, and disorientation were least discriminative.
Extent and Profile of Symptom Change
DISCUSSION
In a large sample of treatment-resistant patients with chronic schizophrenia and acute exacerbation, the rate of response to combined treatment with ECT and flupenthixol was impressive. The short-term efficacy of this combination was at least equal or probably superior to that observed in controlled studies of clozapine or other atypical antipsychotic medications in TRS. 34,40Y42 The value of ECT in TRS would be limited if characterized by a high relapse rate. However, in another work, we have found that the relapse rate after the combination of ECT and flupenthixol is markedly lower when this combined treatment is used as continuation therapy when compared with continuation therapy with ECT alone or with the traditional antipsychotic medication alone. 18 Nonetheless, it must be emphasized that the short-term response rate observed in this study could have been influenced by its uncontrolled nature and the requirement that all patients have acute exacerbation. This study did not focus on testing the relative efficacy of the combination treatment but rather focused on examining the factors predictive of response and characterizing the nature of symptomatic improvement.
The results of poorer outcome with longer duration of current episode and greater severity of baseline negative symptoms in both men and women are similar with our previous study. 16 The new findings include marked sex differences in other clinical features and symptoms associated with response. Moreover, the nature of symptomatic improvement is explored thoroughly in this study.
For decades, it has been thought that the duration of illness and/or the duration of episode is strongly predictive of ECT outcome in schizophrenia. 43Y45 Across sex, we found that when examined conjointly, episode but not illness duration had a powerful predictive value. At a psychometric level, this specificity may have been augmented by assessment of duration of illness being intrinsically less reliable than assessment of episode duration. Clinically, this suggests that the combination of ECT and antipsychotic medication is most effective early in an acute exacerbation, independent of the duration of illness of TRS. Theoretically, this raises the issue of whether prolonged episodes or inadequate treatment exert an iatrogenic effect on responsivity to subsequent treatment. Such concerns have also been raised regarding the potential contributions of prolonged episode duration or inadequate treatment to treatment resistance in major depression. 46, 47 An alternative is that patients with long episodes have a distinct pathophysiology from the outset, although this may be a less likely possibility given the arbitrary timing in the use of ECT-flupenthixol in this TRS sample.
Across sex, we also found that greater severity of negative symptoms also predicted inferior clinical outcome. In these respects, the sex-neutral factors impacting on outcome with combination ECT-flupenthixol may overlap substantially with those traditionally associated with outcome with antipsychotic medications. 48Y50 Although expert groups have traditionally stated that the presence of affective symptoms has positive predictive value for ECT outcome, 51Y54 such symptoms had only modest significance in this study and had no predictive value in other works. 15 The sexes differed in other clinical features and symptoms predictive of outcome. Among males, more frequent psychiatric admissions, paranoid subtype, greater suspiciousness, and lesser blunted affect were associated with response. In essence, a more virulent course associated with paranoid and other delusions was predictive of positive outcome among males. Female responders had a more robust response to ECT-flupenthixol than male responders. Among females, shorter duration of illness, negative family history for schizophrenia, higher baseline MMSE scores, more severe anxiety, guilt feelings, depressive mood, and hallucinatory behavior were associated with response.
There was considerable specificity in the symptom profiles predictive of response as a function of sex. The profile derived among female patients showed a strong correlation with their degree of post-ECT symptomatic improvement but no association when applied to males. In general, sex differences have not been observed in the phenomenology and symptom structure of schizophrenia. 24 To our knowledge, this is the first study using any standardized treatment in schizophrenia to examine sex differences in the clinical features and symptoms predictive of outcome. The findings suggest that although negative symptoms and long episode duration predict negative outcome for both sexes, male and female patients differ strongly in other historical and symptomatic features predictive of response.
In contrast, there were no sex differences in the nature of symptomatic improvement. Similarly, the baseline BPRS factor scores were fairly insensitive to the symptom features and sex differences predictive of clinical outcome but showed strong sensitivity to the pattern of symptom change. In this study, the symptoms of conceptual disorganization, tension, mannerisms and posturing, hostility, and unusual thought content were especially likely to show improvement, whereas 3 symptoms showed significant worsening (motor retardation, blunted affect, and disorientation). As in this study, traditional and atypical antipsychotic medications generally show more benefit for positive than negative symptoms, although in contrast to this study, negative symptoms usually show some degree of improvement with pharmacological treatment. 41, 55, 56 The lack of improvement here in the BPRS withdrawal-retardation factor and the worsening in specific negative symptoms were not likely because of extrapyramidal effects of the antipsychotic medication. Electroconvulsive therapy has marked anti-parkinsonian properties, 45, 52 and extrapyramidal symptoms during ECT are unlikely. 57 Rather, the worsening in specific negative symptoms may have been secondary to the cognitive adverse effects of ECT. Regardless, the findings of this study suggest remarkable specificity in the therapeutic effects of ECT-flupenthixol in TRS. Positive and disorganized symptoms showed consistent improvement. Despite ECT's unequivocal antimanic and antidepressant properties in mood disorders, affective symptoms surprisingly showed only moderate improvement, and specific negative symptoms worsened. Thus, the combination of ECT and a traditional antipsychotic may principally exert antipsychotic effects in TRS, without impacting on other aspects of symptoms.
This study examined a large sample of TRS patients, with a standardized treatment and assessment protocol. The use of a 3-week stabilization period may have enhanced reliability in identifying responders. 17Y21,58,59 One limitation was reliance on clinical consensus for diagnosis, as opposed to a structured instrument. Another limitation was that the study was conducted in Thailand, and the influence of culture-specific influences on symptom expression and assessment cannot be ruled out. This study also used for concurrent treatment a traditional antipsychotic medication that is unavailable in the United States. Although the findings would not likely be different with other traditional antipsychotic medications, this may not be the case if ECT is combined with an atypical antipsychotic. Perhaps, the most important limitation was that prediction of outcome and characterization of symptom change were not contrasted with a pharmacologically treated group, so the generalizability of the findings to other interventions is unknown.
In summary, in patients with TRS who received a combination treatment with ECT and flupenthixol, the response rate was encouraging (54%). Clinically, this combination treatment is most effective early in an acute exacerbation, independent of the duration of illness of TRS. Independence of sex, longer duration of current episode, and greater severity of baseline negative symptoms were predictive of poorer outcome. Duration of illness had weak relations with outcome only among female patients. There were marked sex differences in other clinical features and symptoms associated with response. The treatment resulted in marked improvement in specific positive symptoms, with an intermediate effect on affective symptoms and no effect on or worsening of specific negative symptoms.
